Takeda Pharmaceutical Company Limited
TAK · NYSE
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Market Cap | $7,159,101 | $6,486,041 | $6,788,722 | $5,447,459 |
| - Cash | $385,113 | $457,800 | $533,530 | $849,695 |
| + Debt | $4,515,265 | $4,843,752 | $4,382,341 | $4,345,411 |
| Enterprise Value | $11,289,253 | $10,871,993 | $10,637,533 | $8,943,175 |
| Revenue | $4,581,551 | $4,263,762 | $4,027,478 | $3,569,006 |
| % Growth | 7.5% | 5.9% | 12.8% | – |
| Gross Profit | $3,001,334 | $2,832,257 | $2,783,406 | $2,462,160 |
| % Margin | 65.5% | 66.4% | 69.1% | 69% |
| EBITDA | $1,210,512 | $1,143,936 | $1,284,067 | $1,183,213 |
| % Margin | 26.4% | 26.8% | 31.9% | 33.2% |
| Net Income | $107,928 | $144,067 | $317,017 | $230,059 |
| % Margin | 2.4% | 3.4% | 7.9% | 6.4% |
| EPS Diluted | 33.62 | 45.58 | 100.97 | 72.94 |
| % Growth | -26.2% | -54.9% | 38.4% | – |
| Operating Cash Flow | $1,057,182 | $716,344 | $977,156 | $1,123,105 |
| Capital Expenditures | -$200,795 | -$480,730 | -$633,689 | -$186,037 |
| Free Cash Flow | $856,387 | $235,614 | $343,467 | $937,068 |